Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature.

克唑替尼相关肾囊肿的发生可能与 ALK 阳性非小细胞肺癌患者无进展生存期延长有关 ： 病例报告及文献复习.

• 发表时间: Jun 2021
• 来源期刊: Clin Case Rep
• DOI: 10.1002/ccr3.4278
• PMID: 34136235
• 文章类型: Case Reports
• 作者列表: Wiest NE,Tzou KS,Olson MT,Herchko SM,Bajalia EM,Thiel DD,Lou Y,Zhao Y,Manochakian R

关键词: ALK positive; crizotinib; non‐small‐cell lung cancer; progression‐free survival; renal cysts

Abstract

Non-small cell lung cancer patients with anaplastic lymphoma kinase or c-ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib-associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression-free survival.

摘要

接受酪氨酸激酶抑制剂克唑替尼治疗的具有间变性淋巴瘤激酶或c-ros癌基因1突变的非小细胞肺癌患者很少发生克唑替尼相关肾囊肿（CARC）。这里,我们提供了病例报告和文献综述,支持CARC可能与无进展生存期正相关的假设.